![](/images/graphics-bg.png)
Fulminant Diabetes in a Patient with Advanced Melanoma on Nivolumab
المؤلفون المشاركون
Chokr, Nora
Farooq, Hafsa
Guadalupe, Elizabeth
المصدر
Case Reports in Oncological Medicine
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-4، 4ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-01-28
دولة النشر
مصر
عدد الصفحات
4
التخصصات الرئيسية
الملخص EN
Background.
Anti-PD-1 agents were approved for advanced melanoma after the landmark trial Checkmate-037.
Anti-PD-1 agents can breach immunologic tolerance.
Fulminant diabetes is an immune endocrinopathy that results from a violent immune attack leading to complete destruction of pancreatic beta cells in genetically predisposed people.
We present a rare case of fulminant diabetes precipitated by anti-PD-1 immunotherapy.
Case.
A 61-year-old male with advanced melanoma presented with a three-day history of nausea, vomiting, and malaise.
He was started on nivolumab and ipilimumab.
After the third dose, he developed a generalized rash and was prescribed high-dose prednisone.
Labs revealed potassium 9.5 mmol/L, sodium 127 mmol/L, bicarbonate <10 mmol/L, blood glucose 1211 mg/dL, anion gap >31 mmol, arterial blood pH 7.14, and beta-hydroxybutyrate 13.7 mmol/L.
He was diagnosed with diabetic ketoacidosis.
Hemoglobin A1C was 6.9%.
C-peptide was undetectable (<0.1 ng/ml).
Glutamic acid decarboxylase autoantibodies, zinc transporter 8 autoantibodies, insulin autoantibodies, islet antigen 2 autoantibodies, and islet cell antibodies were all negative.
Conclusion.
Anti-PD-1 immunotherapy is effective in cancers refractory to standard chemotherapy.
These agents can precipitate autoimmune disorders.
As the use of anti-PD-1 agents is expected to rise, physicians should be educated about the potential side effects.
We recommend conducting routine blood glucose checks in patients on these agents.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Chokr, Nora& Farooq, Hafsa& Guadalupe, Elizabeth. 2018. Fulminant Diabetes in a Patient with Advanced Melanoma on Nivolumab. Case Reports in Oncological Medicine،Vol. 2018, no. 2018, pp.1-4.
https://search.emarefa.net/detail/BIM-1146643
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Chokr, Nora…[et al.]. Fulminant Diabetes in a Patient with Advanced Melanoma on Nivolumab. Case Reports in Oncological Medicine No. 2018 (2018), pp.1-4.
https://search.emarefa.net/detail/BIM-1146643
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Chokr, Nora& Farooq, Hafsa& Guadalupe, Elizabeth. Fulminant Diabetes in a Patient with Advanced Melanoma on Nivolumab. Case Reports in Oncological Medicine. 2018. Vol. 2018, no. 2018, pp.1-4.
https://search.emarefa.net/detail/BIM-1146643
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1146643
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)